Skip to content
ClinCalc Pro
Menu
Haematology Strong — NICE NG52 / Binet 1981

Binet Staging System for CLL

Binet clinical staging for Chronic Lymphocytic Leukaemia based on number of lymph node areas and cytopenias. Guides treatment initiation.

5 areas: cervical, axillary, inguinal lymph nodes (unilateral or bilateral = 1 area each), liver, spleen

Score interpretation

Binet Stage A 0–1

Binet Stage A: < 3 lymphoid areas, no anaemia, no thrombocytopenia. Median survival similar to age-matched controls.

→ Watch and wait. No treatment unless symptomatic (bulky lymphadenopathy, B symptoms, cytopenias, doubling time < 6 months). 3–6-monthly clinic reviews. No treatment benefit shown for early intervention.

Binet Stage B 2

Binet Stage B: ≥ 3 areas involved, no cytopenias. Median survival ~7 years.

→ Initiate treatment if: progressive disease, B symptoms, doubling time < 6 months, autoimmune haemolysis, or significant lymphadenopathy. First-line: FCR (fludarabine/cyclophosphamide/rituximab) if fit; ibrutinib ± rituximab if IGHV unmutated or del(17p); venetoclax + obinutuzumab for unfit. FISH for del(17p) / TP53 before treatment.

Binet Stage C 3–99

Binet Stage C: Haemoglobin < 100 g/L or platelets < 100 ×10⁹/L due to bone marrow infiltration. Treatment always indicated.

→ Initiate treatment: venetoclax + obinutuzumab (preferred for older/comorbid patients). Ibrutinib or acalabrutinib if del(17p) or TP53 mutation. FCR if young and fit, IGHV mutated. Exclude autoimmune haemolysis (DAT, reticulocytes) — treat separately if present.

Interpretation bands for the Binet CLL. Apply clinical judgement and local guidance.

References

Related

Curated clinical cross-links plus same-class fallbacks.

Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.